Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Apellis Pharmaceuticals
Apellis Pharmaceuticals
(APLS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Empaveli
Pegcetacoplan
2021-05-14
2026-2038
Paroxysmal hemoglobinuria
Syfovre
Pegcetacoplan
2023-02-17
2026-2038
Paroxysmal hemoglobinuria
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Pegcetacoplan
ischemic stroke
,
cerebral infarction
,
reperfusion injury
,
thromboinflammation
,
wet macular degeneration
,
hemolytic anemia
,
amyotrophic lateral sclerosis
,
motor neuron disease
,
sclerosis
,
kidney diseases
,
iga glomerulonephritis
,
membranous glomerulonephritis
,
lupus nephritis
,
nephritis
,
anemia
,
hemolysis
,
ovarian neoplasms
,
endometrioid carcinoma
,
serous cystadenocarcinoma
,
fallopian tube neoplasms
,
carcinosarcoma
,
acinar cell carcinoma
,
pancreatic ductal carcinoma
,
pancreatic neoplasms
,
geographic atrophy
,
macular degeneration
,
paroxysmal hemoglobinuria
,
hemoglobinuria
,
atrophy
,
kidney transplantation
,
hemolytic anemia autoimmune
,
chronic kidney failure
,
delayed graft function
,
glomerulonephritis
,
membranoproliferative glomerulonephritis
,
rare diseases
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use